Exosome Production From hMSC Using The iCELLis Fixed-Bed Bioreactor

By Yangyang Shen, Miaozhu Wang, Yachao Zhao, Cheng'en Wu, Jianwu Wang, ECHO Biotechnology, and George Qi Zhang, Kangyang Zheng, Yuqing Li, Andrew Low, Peiqing Zhang, Cytiva

This poster presents a scalable, high-yield process for producing exosomes from human mesenchymal stromal cells (hMSC) using the iCELLis Nano fixed-bed bioreactor. Compared to two other bioreactor systems (T1 and T2), iCELLis Nano demonstrated superior performance in exosome yield per unit area, particle recovery rate, and purity. The downstream purification process, based on tangential flow filtration (TFF), preserved high biological activity, with strong IL6 and IL27 inhibitory effects. The data also highlight the iCELLis Nano’s efficient nutrient utilization and lower levels of metabolic byproducts, contributing to its overall process efficiency. With consistent expression of key exosomal markers and robust anti-inflammatory activity, this platform offers a compelling solution for industrial-scale exosome manufacturing.

For teams exploring therapeutic applications of extracellular vesicles, gain valuable insights into optimizing upstream and downstream workflows.